Wire Stories
692Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of...
- 780
Accenture Helps Rakuten Mobile Launch Fully Virtualized Cloud-Native Mobile Network
New mobile network brings all the telecommunication provider’s operations to the cloud NEW YORK & TOKYO–(BUSINESS WIRE)–Accenture (NYSE: ACN) has helped Rakuten...
- 798
OPENEDGES Signs Semiconductor Design IP License Agreement With Top-Tier Global Semiconductor Company
OPENEDGES is a leader in AI Semiconductor Design IP SEOUL–(BUSINESS WIRE)–OPENEDGES Technology, Inc., the world’s leading supplier of AI computing IP solutions,...
- 765
Shardul Amarchand Mangaldas & Co. Enables Work from Anywhere with Citrix®
Leading law firm uses digital workspace solutions to deliver consistent, secure and reliable experience that empowers employees to perform at their best...
- 701
Intercontinental Exchange Launches 10 New MSCI® Index Futures
Four New Contracts Help Manage Climate Risk and Are Only Available on ICE Futures U.S. The Additional Six Contracts Provide Specific Regional...
- 913
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of TROPION-Lung01,...
- 1.0K
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic Alterations
TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of TROPION-Lung05,...
- 736
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
– Hillhouse-backed Overland Pharmaceuticals to initially contribute $50 million to fund operations and development LAUSANNE, Switzerland & SHANGHAI & BOSTON–(BUSINESS WIRE)–ADC Therapeutics...
- 721
Can-Fite Reports on Progress With Its Namodenoson NASH Program
Top NASH U.S. Key Opinion Leaders advise on the design of a Phase IIb protocol Manufacturing of Namodenoson for the Phase IIb...
- 765
Gravity Launches an Idle Casual RPG ‘Poring Merge’ for the First Time in Brazil
A new idle casual RPG that anyone can easily enjoy With pre-registration by over 300,000 users, it is expected to gain high...
